
Insulet Corporation: financial statements
Price
$145.86
November 16, 2026Market cap $10.3B
What Ploutos Investor adds for Insulet
Part of Ploutos Investor, €9.99 a month
- The full history: 17 fiscal years, from 2009
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Financial statements
Each fiscal year's income statement, balance sheet and cash flow as the company filed them, and the latest quarters.
Click a line to see it on the chart.
Revenue
+26.3% a year over 2 years
| Line | 2023 | 2024 | 2025 | Average a year |
|---|---|---|---|---|
| Revenue | $1.7B | $2.1B | $2.7B | +26.3% |
| Cost of revenue | $537M | $626M | $768M | +19.6% |
| Gross profit | $1.2B | $1.4B | $1.9B | +29.3% |
| Operating income | $220M | $309M | $474M | +46.7% |
| Net income | $206M | $418M | $247M | +9.4% |
| Earnings per share | $2.94 | $5.78 | $3.48 | +8.8% |
| Earnings per share, basic | $2.96 | $5.97 | $3.51 | +8.9% |
| Margins | ||||
| Gross margin | 68.3% | 69.8% | 71.6% | |
| Operating margin | 13.0% | 14.9% | 17.5% | |
| Net margin | 12.2% | 20.2% | 9.1% | |
Financial statements
PODD's revenue, profits and cash flows from 2009 to 2022, 14 more fiscal years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 5 fiscal years.
By segment
Revenue and operating income by business segment or by product, as the company itself reports them in each year's 10-K. Each year from the latest filing that carries it, so a segment renamed or re-cut shows in its current form.
- U.S.Omnipod
- International Omnipod
- Drug Delivery
- 2023: U.S.Omnipod $1.3B, International Omnipod $410M, Drug Delivery $36M
- 2024: U.S.Omnipod $1.5B, International Omnipod $523M, Drug Delivery $39M
- 2025: U.S.Omnipod $1.9B, International Omnipod $754M, Drug Delivery $34M
| Product | 2023 | 2024 | 2025 | Share 2025 |
|---|---|---|---|---|
| U.S.Omnipod | $1.3B | $1.5B | $1.9B | 71% |
| International Omnipod | $410M | $523M | $754M | 28% |
| Drug Delivery | $36M | $39M | $34M | 1.3% |
By segment
PODD's revenue by product line from 2014 to 2022, 9 more fiscal years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 5 fiscal years.
From the XBRL of 16 of the company's annual reports to the SEC (ASC 280). Amounts in dollars.
Amounts are in dollars as the company filed them in its annual reports (10-K or 20-F). Those reporting in another currency are converted at each fiscal year-end rate. Shares and earnings per share are adjusted for splits.
Debt and obligations
What the company owes beyond the loans on its balance sheet, and when it pays, from the notes to its annual report: debt maturities, leases, pension plans, goodwill by segment, and how it gets to the tax it pays.
When the debt falls due
Dec 31, 2025Due within 2 years
$38M
Principal of loans and bonds falling due, from the annual report dated December 31, 2025, without leases and interest. The filing
- 2026: $18M
- 2027: $19M
Leases
Dec 31, 2025Operating leases
$52M
Finance leases
–
The liability is the present value of the rent still to pay, at December 31, 2025. It is not counted in the ladder's debt. The filing
Goodwill by segment
Dec 31, 2025Total goodwill
$52M
The company does not state its goodwill by segment, at December 31, 2025. The filing
From the statutory to the effective tax rate, 2025
Dec 31, 2025Statutory rate
21.0%
Effective rate
27.2%
The company paid 27.2% in tax on its profit, 6.2 points above the US federal rate (21.0%). Below, the reasons it gives.
Statutory rate
21.0%
Non-deductible expenses
+6.7 pts
Difference the filing does not itemize
-0.5 pts
Effective rate
27.2%
One point is 1% of profit before tax. The lines are as the company states them in the notes to its annual report. The filing
Earnings quality
How the reported earnings were made, read from the filings. A description, not a score: our tests found no link between these measures and later share returns.
Taxes: deferred and paid
The deferred part was 67.4% of the tax charge in the year to Dec 31, 2025.
Cash taxes paid were 127.9% of the current tax charge in the year to Dec 31, 2025.
- Deferred share, year to Dec 31, 2025$62M of $92M
- 67.4%
- $39M paid, $30M current
- 127.9%
When profit in the accounts runs ahead of taxable profit, the deferred part grows. It also moves for reasons unrelated to how earnings are booked: tax-law changes, the use of past losses, and the US rule since 2022 that spreads research costs over five years. Where the notes report it, the tax-rate bridge under Debt and obligations shows how the rate gets from the statutory one to the effective one.
The earnings per share split is not shown: net income over the diluted share count does not match the earnings per share the company filed, so the parts would not add up to it.
Receivables and inventory against sales are not shown: a figure it needs is missing from the company's structured filings.
The allowance for doubtful accounts is not shown: the company does not tag it in its structured filings.
A reading is called out when it is above the 90th percentile of the same reading across the S&P 500, or, for a fall, below the 10th, as measured on 9 November 2026. Each part uses only the company's own filings.
The full analysis
What do Insulet's filings show?
These are Insulet's figures from its filings. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
How much revenue did PODD have in 2025?
Insulet had revenue of $2.7B and net income of $247M in fiscal 2025, a net margin of 9.1%.
How much debt does PODD have?
On December 31, 2025 Insulet had total assets of $3.2B, debt of $949M and shareholders' equity of $1.5B.
How much free cash flow does PODD have?
In fiscal 2025 Insulet had cash from operations of $569M and spent $192M on capital expenditure, leaving $378M of free cash flow.
Where are the figures from?
From Insulet Corporation's annual and quarterly reports to the SEC, read from the structured data (XBRL) it files itself.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.